Toggle navigation
Home
Search
Services
Blog
Contact
About
Antibody-Drug Conjugate Therapy for Cancer Treatment
Chari, Ravi V.
Immunogen, Inc., Cambridge, MA, United States
Search 16 grants from Ravi Chari
Search grants from Immunogen, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Zika Virus and Related Arbovirus Infections in Deferred Blood Donors
Determinants of organelle-specific activation of Proprotein Convertase 1
Post-Trial Access for Insured and Uninsured Participants
Toxicological Significance of Alkylbenzene Metabolism
Human T-Cell Subsets - Isolation and Characterization
Recently added grants:
Development of a new molecular predictor for risk of distant metastases in melanoma
Symposium on Cognitive Auditory Neuroscience (SCAN)
Amygdala Mediated Mechanisms Regulating Visceral Pain
The Roles of Complement Activation vs. Shiga Toxin Binding to Endothelium in eHUS.
Regulation of Niche Cell Differentiation to Sustain Intestinal Stem Cell Regeneration Against Gut Inflammation
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44CA056209-02A3
Application #
2008020
Study Section
Special Emphasis Panel (ZRG2-SSS-4 (02))
Project Start
1992-07-01
Project End
1999-03-31
Budget Start
1997-07-11
Budget End
1998-03-31
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Institution
Name
Immunogen, Inc.
Department
Type
DUNS #
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Related projects
NIH 1998
R44 CA
Antibody-Drug Conjugate Therapy for Cancer Treatment
Chari, Ravi V. / Immunogen, Inc.
NIH 1997
R44 CA
Antibody-Drug Conjugate Therapy for Cancer Treatment
Chari, Ravi V. / Immunogen, Inc.
Publications
Xie, Hongsheng; Audette, Charlene; Hoffee, Mary et al.
(2004)
Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice.
J Pharmacol Exp Ther 308:1073-82
Comments
Be the first to comment on this grant